Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
核心洞察
Monod Bio (搜索) and SignalChem Biotech (搜索), a wholly owned subsidiary of Sino Biological (搜索), announced a non-exclusive licensing agreement covering LuxSit (搜索) de novo luciferase technology and NovoBodies (搜索).
SignalChem Biotech (搜索) may incorporate the AI-designed protein technologies into custom luminescent assay development and protein-fusion services for research use.
The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological (搜索)'s strategy of integrating AI-enabled technologies across its life science tools portfolio.
Monod Bio (搜索), a Seattle-based AI-enabled protein design company, and SignalChem Biotech (搜索) Inc., a wholly-owned subsidiary of Sino Biological (搜索), Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit (搜索) de novo luciferase technology and NovoBodies (搜索). The agreement, announced on August 26, 2026, enables SignalChem Biotech to incorporate these AI-designed protein technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use.
The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological (搜索)'s broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.
"By incorporating Monod Bio (搜索)'s AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly," said Dr. Rob Burgess, Chief Business Officer of Sino Biological (搜索). "This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
The Licensed Technologies
Monod Bio (搜索)'s LuxSit (搜索) is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies (搜索) are compact, highly stable binding proteins engineered for high-performance recognition of various targets. Together, the technologies provide versatile tools for developing customized assays and discovery workflows.
"SignalChem Biotech (搜索) and Sino Biological (搜索) have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base," said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio (搜索). "This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
Strategic Significance
The agreement reflects Sino Biological (搜索)'s broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio. SignalChem Biotech (搜索), as a wholly owned subsidiary, provides specialized reagents and CRO services supporting drug discovery and life science research, while Sino Biological operates as an international life science tools provider with facilities across Asia, North America and Europe.
Monod Bio (搜索) uses AI-powered de novo protein design to create novel binders, biosensors and other functional proteins for research and diagnostic applications. Through its Monod Inside model, the company partners with life science companies to integrate its technologies into next-generation products and services.
Sino Biological (搜索) noted in its disclosure that the development of the related business may be affected by various factors, including changes in market demand. Given the company's broad product portfolio, the revenue associated with this business is not expected to have a material impact on the company's overall financial performance.